Navigation Links
Discovery Labs to Present AFECTAIR® Data at European Congress on Pediatric and Neonatal Ventilation
Date:6/7/2012

WARRINGTON, Pa., June 7, 2012 /PRNewswire/ -- Discovery Laboratories, Inc. (Nasdaq: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced it will be presenting neonatal AFECTAIR® data at the 11th European Congress on Pediatric and Neonatal Ventilation being held June 6 – 9, 2012 in Montreux, Switzerland.  Though initially presented in the U.S., these data presentations mark the first introduction of the AFECTAIR neonatal device through scientific exchange to a European pediatric critical care audience.  The AFECTAIR neonatal device has been developed by Discovery Labs to simplify the delivery of inhaled medications for critical care patients requiring ventilatory support and was cleared for marketing in the U.S. in early 2012.  The AFECTAIR neonatal device will be commercially available in the U.S. and EU in late 2012.  

Highlights from the two data presentations include:

Utilization of iNO Using a Novel Ventilator Circuit Connector versus Standard of Care Under Simulated Neonatal Mechanical Ventilation Conditions – An In Vitro Study.  Mazela, et al.

  • The Standard of Care (SoC) for ventilator delivery of inhaled nitric oxide (iNO) in pulmonary hypertension allows for potential iNO dilution, gas loss and environmental contamination.
  • According to this study, which simulated neonatal mechanical ventilation conditions using an in vitro model, use of the AFECTAIR neonatal device resulted in the achievement of target nitric oxide concentrations using less nitric oxide when compared to the SoC delivery apparatus. 

In Vitro Assessment of a Novel Aerosol Delivery System under Simulated Conditions; Mazela, et al.

  • According to this study conducted in an in vitro model of neonatal mechanical ventilation conditions, when compared with a conventional wye connector, use of the AFECTAIR neonatal device resulted in improved delivery of aerosolized albuterol sulfate, including:     
    • a nine-fold increase in delivered dose under simulated CPAP conditions
    • a 14-fold increase in delivered dose under simulated mechanical ventilation conditions
    • a smaller difference in particle size distribution between aerosol output from the nebulizer and aerosol output from the patient interface.

These data will be presented on June 8th at the Montreux Congress Center.

About Discovery Labs

Discovery Laboratories, Inc. is a specialty biotechnology company with one focus – to create life-saving products for critical care patients with respiratory disease and improve the standard of care for pulmonary medicine. Discovery Labs' novel proprietary KL4 surfactant technology produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant and is being developed in liquid, lyophilized and aerosolized formulations. Discovery Labs is also developing its proprietary drug delivery technologies – capillary aerosol generator and novel patient interface connectors – to enable efficient, targeted upper respiratory or alveolar delivery of aerosolized KL4 surfactant. Discovery Labs believes that its proprietary technology makes it possible, for the first time, to develop a significant pipeline of surfactant products to address a variety of respiratory diseases for which there frequently are few or no approved therapies. For more information, please visit our website at www.discoverylabs.com.

Forward Looking Statements

To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Examples of such risks and uncertainties, including those related to Discovery Labs' development activities, including preclinical activities exploring the potential utility of the AFECTAIR neonatal device, are described in Discovery Labs' filings with the Securities and Exchange Commission, including the most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto. Except as otherwise required by law, Discovery Labs undertakes no obligation to update or revise any forward-looking statements.


'/>"/>
SOURCE Discovery Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Discovery Labs Reports First Quarter 2012 Financial Results
2. Genomic Health and OncoMed Announce Strategic Alliance for Biomarker Research and Discovery Using Next Generation Sequencing
3. AnaptysBio Announces Antibody Discovery Partnership With Gilead Sciences
4. UWM discovery advances graphene-based electronics
5. Mars, Incorporated Answers Question: How Does Feeding People and Pets Nurture Science and Discovery? At TEDMED 2012
6. AlphaBio Centrix, LLC Announces a New Discovery for Programming Energetic Patches
7. Discovery in Nature elucidates immune cells in skin and supports novel vaccine approach
8. Thomson Reuters Cortellis Drives Drug Discovery and Development With Powerful New Web Services
9. Discovery opens door to low-cost negative refraction, new products and industries
10. AnaptysBio Announces New Strategic Antibody Discovery
11. Thomson Reuters Research Forecasts the Onset of the Targeted Drug Discovery Era
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... YORK , March 23, 2017 ... ... of death, putting significant strain on health care systems, in ... cancer diagnoses rises, so too does the development of innovative ... minimum side effects. Among the many types of cancer treatments, ...
(Date:3/23/2017)... ... March 23, 2017 , ... Advanced Polymer Monitoring Technologies ... Dr. Sigmund “Sig” Floyd as Vice President ? Global Business Development. Dr. Floyd ... , “Dr. Floyd’s career has spanned 30 years in the chemicals and equipment ...
(Date:3/22/2017)... MONICA, Calif. , March 22, 2017 /PRNewswire/ ... are proud to announce their extended partnership and ... will be headlined by the 21 st ... BIOMEDevice Boston, taking place May 3-4, 2017. ... Advanced Medical Technology Association (ADVAMED) President and CEO, ...
(Date:3/22/2017)... New York , March 22, 2017 ... is largely fragmented, states a research report by Transparency ... S.A., Pfizer Inc., Amgen Inc., and AbbVie Inc., accounted ... in 2015. The prominent players in this market are ... expand their product portfolio, which is likely to lead ...
Breaking Biology Technology:
(Date:2/24/2017)... BARCELONA, Spain , Feb. 24, 2017  EyeLock LLC, ... will demonstrate its elite iris biometric solution on ... with X16 LTE at Mobile World Congress ... in Qualcomm,s Booth in Hall 3, Stand ... contains the Qualcomm Haven™ security platform—a combination ...
(Date:2/14/2017)... Feb. 14, 2017  Wake Forest Baptist Medical Center ... new chief executive officer (CEO). Freischlag joins the medical ... D. McConnell , M.D., who last year announced that ... Medical Center, after leading it since 2008.   ... of Wake Forest Baptist,s academic health system, which includes ...
(Date:2/8/2017)... About Voice Recognition Biometrics Voice recognition biometrics ... a stored voiceprint template. Acoustic features of an ... are compared to distinguish between individual voices. Voice ... PCs already have a microphone and can authenticate ... are most likely to be deployed in telephone-based ...
Breaking Biology News(10 mins):